Guardant Health (GH) Stock Forecast & Price Target

$41.98 +0.20 (+0.47%)

As of 11:09 AM Eastern

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 20 Analyst Ratings

Sell
0

Hold
0

Buy
20

Based on 20 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 20 analysts, 20 have given a buy rating for GH.

Consensus Price Target

$48.95
16.61% Upside

According to the 20 analysts' twelve-month price targets for Guardant Health, the average price target is $48.95. The highest price target for GH is $60.00, while the lowest price target for GH is $32.00. The average price target represents a forecasted upside of 16.61% from the current price of $41.98.

Get the Latest News and Ratings for GH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Guardant Health and its competitors.

GH Analyst Ratings Over Time

Type	Current Forecast 4/8/24 to 4/8/25	1 Month Ago 3/9/24 to 3/9/25	3 Months Ago 1/9/24 to 1/8/25	1 Year Ago 4/9/23 to 4/8/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	20 Buy rating(s)	20 Buy rating(s)	15 Buy rating(s)	10 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.95	$48.40	$40.60	$41.30
Forecasted Upside	16.61% Upside	23.09% Upside	10.96% Upside	121.33% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Remove Ads

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Guardant Health Stock vs. The Competition

Type	Guardant Health	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	17.16% Upside	18,047.48% Upside	33.19% Upside
News Sentiment Rating	Positive News See Recent GH News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/26/2025	Stephens 4 of 5 stars	Mason Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00	+18.57%
3/6/2025	Morgan Stanley 3 of 5 stars	Shannon O'Callaghan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$42.00 ➝ $52.00	+26.78%
2/26/2025	Piper Sandler 2 of 5 stars	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$34.00 ➝ $50.00	+15.92%
2/24/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$47.00 ➝ $52.00	+20.59%
2/24/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$56.00 ➝ $56.00	+29.86%
2/24/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kyle Mikson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$42.00 ➝ $60.00	+39.96%
2/21/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Sykes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$49.00 ➝ $56.00	+31.12%
2/21/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $59.00	+32.80%
2/21/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rachel Vatnsdal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$50.00 ➝ $55.00	+18.48%
2/21/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$45.00 ➝ $53.00	+15.59%
Get the Latest News and Ratings for GH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.
1/23/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$60.00	+27.12%
10/30/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$40.00 ➝ $35.00	+49.51%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$60.00 ➝ $50.00	+131.27%
8/21/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+42.30%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+48.27%
8/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $42.00	+38.61%
8/8/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $37.00	+21.79%
7/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $50.00	+37.51%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $40.00	+22.89%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+17.09%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
9/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$60.00 ➝ $55.00	+129.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:55 AM ET.

Should I Buy Guardant Health Stock? GH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 2, 2025. Please send any questions or comments about these Guardant Health pros and cons to contact@marketbeat.com.

Guardant Health
Bull Case

Here are some ways that investors could benefit from investing in Guardant Health, Inc.:

Guardant Health, Inc. has recently seen a significant increase in institutional investment, with Nikko Asset Management Americas Inc. increasing its stake by 15.6%, indicating strong confidence in the company's future performance.
The company has a robust portfolio of innovative products, including the Guardant360 Response Test, which is designed for advanced cancer treatment, showcasing its commitment to precision oncology.
Recent analyst reports have been optimistic, with Canaccord Genuity raising the price target to $60.00, reflecting a positive outlook on the stock's potential growth.
Guardant Health, Inc. is at the forefront of cancer research collaborations, including a partnership with Illumina, Inc., which enhances its research capabilities and market position.
The current stock price of Guardant Health, Inc. is approximately $44.73, which may present a buying opportunity for investors looking to enter at a favorable valuation.

Guardant Health
Bear Case

Investors should be bearish about investing in Guardant Health, Inc. for these reasons:

Despite recent growth, Guardant Health, Inc. operates in a highly competitive market, which could impact its market share and profitability in the long term.
The company is heavily reliant on the success of its product pipeline, and any delays or failures in product development could adversely affect its stock performance.
Institutional investors currently hold 92.60% of the company's stock, which may lead to volatility if large shareholders decide to sell their positions.
Market conditions and regulatory changes in the healthcare sector could pose risks to the company's operations and financial stability.
Guardant Health, Inc. has yet to achieve consistent profitability, which may deter risk-averse investors looking for stable returns.

GH Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $48.95, with a high forecast of $60.00 and a low forecast of $32.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 20 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GH shares.
: According to analysts, Guardant Health's stock has a predicted upside of 16.61% based on their 12-month stock forecasts.
: Guardant Health has been rated by research analysts at Barclays, Canaccord Genuity Group, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Scotiabank, Stephens, Stifel Nicolaus, and The Goldman Sachs Group in the past 90 days.
: Analysts like Guardant Health more than other "medical" companies. The consensus rating for Guardant Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:GH) was last updated on 4/8/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Guardant Health (GH) Stock Forecast & Price Target